District – Nesvizh, project – pharmaceutics: the Development Bank continues to strengthen regions as part of a large-scale initiative
The pharmaceutical industry of Belarus is a strategically important sector of the economy to ensure security in the field of healthcare, medicine, medical and technical equipment. To improve the management system of this area in the republic, the Belpharmprom holding was established in 2017, which includes nine large specialized organizations. However, the private sector is also actively working to saturate the Belarusian market with high-quality and affordable medicine.
One of the examples of a successful pharmaceutical business is the Med-Interplast enterprise. It produces medicine in hard gelatin capsules and powders for the preparation of solutions or suspensions for oral administration. It is worth noting that production is carried out according to the full cycle method: from control of the incoming substance to the final product. It allows us to produce high-quality medicine, the demand for which is not only in the domestic market - every year the company systematically increases the export component.
To meet the needs of consumers as much as possible, an investment project has been implemented by Med-Interplast to launch a new line for the production of medicine in the format of tablets and capsules. The emergence of modern production in Nesvizh was facilitated by the program "One district - one project", within the framework of which the Development Bank provided financial support to the enterprise.
Visiting Med-Interplast, Inga Tarnovskaya, head of Minsk branch of the Development Bank, noted that the results of the joint work of the Bank and the company were impressive. And this is true. As part of the investment project, a new production building was built, which meets all the strictest requirements for the production of pharmaceutical products. It has modern high-tech equipment, all the engineering networks necessary for its functioning, and most importantly, new jobs have been created. To operate the new line at full production load, it will be necessary to hire 70 people.
The implemented investment project will effectively strengthen the existing pharmaceutical production from an economic point of view. An increase in production and, as a result, sales of products are planned for this year, and maximum capacity will be reached in 2026. This will make it possible to produce more than 600 thousand packages of tablets annually, which is 4.5 times more than before the implementation of the investment project. In addition, the production of capsules will also be increased to more than 1.4 million packages per year, which is almost 3 times more than it was.
It is also planned to master the production of 24 new medicines in capsules and tablets by Med-Interplast. It is assumed that their annual production volume will be more than 1 million packages.
"Such creative activities of Belarusian business and the country's programs to support private initiatives, without exaggeration, effectively affect the economic well-being of the regions and the whole country, and in this case, also impact positively on population health," Inga Tarnovskaya said in an interview with the head of the enterprise.
Andrey Trizonov, Director of Med-Interplast, said that the new production line would soon begin manufacturing medicines in accordance with GMP standards for treatment of diseases of gastrointestinal tract and musculoskeletal system, colds, as well as neurological, gastroenterological spectrum and others. These drugs will be supplied both to the domestic market and for export.
telegram1.png Subscribe to our Telegram channel in order to quickly receive up-to-date information about the activities of the Development Bank.
